Human papillomavirus (HPV) is a startlingly common sexually transmitted disease. In fact, experts estimate that around 70% of sexually active adults will contract the virus at some point in their lives. Up until very recently, the treatment for this widespread condition dealt only with preventing the HPV infection or minimizing the symptoms; both doctors and their patients were resigned to the thought that there was no cure for HPV. New research, however, suggests that Active Hexose Correlated Compound (AHCC) could be an effective and natural treatment for HPV.
Before we look at the study, though, what exactly is HPV? What is AHCC?
In reality, HPV is a sort of umbrella-term that describes 230 different strains of the virus, of which only 100 strains of the virus have been found in humans. Each type of HPV varies slightly in symptoms and severity, with some types being completely asymptomatic. At least fifteen forms of HPV, though, are considered “high-risk” because of their association with cancer according to the World Health Organization.
According to the Centers for Disease Control, these high-risk versions of the virus are responsible for around:
- 99% of cervical cancers
- 95% of anal cancer
- 60% of oropharyngeal cancer
- 65% of vaginal cancer
- 50% of vulvar cancer
- 35% of penile cancer
Because of its strong connection with various forms of cancer, HPV has been a major source of concern for healthcare professionals. As mentioned, though, prevention was the strongest form of defense known.
Active Hexose Correlated Compound, or AHCC, is naturally extracted from the roots of Japanese medicinal mushrooms. A large body of research has shown that AHCC strengthens the body's natural immune response by increasing the number and activity of the various immune cells. Based on this strong scientific backing, AHCC has seen much use in clinic settings to treat a host of conditions including several forms of cancer.
AHCC is also in wide use by individuals to improve their immune response year-round and prevent an incidental infection.
A recent study, however, hints at an exciting new use for AHCC as a natural treatment for HPV.
A new clinical pilot study conducted by Dr. Judith Smith and funded independently by UTHealth Medical School at Houston evaluated ten HPV-positive women with half the group taking 3g of AHCC once daily for 1-3 months and half for 3 up to 6 months. At the end of the 3 to 6 month trial, five of the women achieved a negative HPV test result during the study– three with confirmed eradication after stopping AHCC!
Previous research had shown that AHCC eradicated the expression of HPV strains in mice.
Based on these positive preliminary results, the research is already moving on to the second phase – a randomized, double-blind, placebo-controlled cross-over human study at UTHealth Medical School at Houston. If you are interested in enrolling, please click here.
While this field of study is still in the early stages of its development, the results seem promising that AHCC could be a natural treatment for HPV infections.